News Sanofi’s Aubagio recommended for use on UK’s NHS HannahBlake 0 Comment The UK’s National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to Share X Sanofi’s Aubagio recommended for use on UK’s NHS https://pharmaphorum.com/news/sanofis-aubagio-recommended-for-use-on-uks-nhs/
News Phase 3 goal met by Novartis’ multiple myeloma drug HannahBlake 0 Comment Novartis’ investigational compound, LBH589, for multiple myeloma has met its primary endpoint in phase 3 clinical trials. LBH589 Share X Phase 3 goal met by Novartis’ multiple myeloma drug https://pharmaphorum.com/news/phase-3-goal-met-by-novartis-multiple-myeloma-drug/
News Lilly’s depression drug fails to meet goal in phase 3 HannahBlake 0 Comment Eli Lilly and Company’s edivoxetine did not meet its primary endpoint in phase 3 clinical trials as an Share X Lilly’s depression drug fails to meet goal in phase 3 https://pharmaphorum.com/news/lilly-s-depression-drug-fails-to-meet-goal-in-phase-3/
Cancer/ News Roche, Molecular Partners in cancer deal worth over $1 billion HannahBlake 0 Comment Roche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new Share X Roche, Molecular Partners in cancer deal worth over $1 billion https://pharmaphorum.com/news/roche-molecular-partners-in-cancer-deal-worth-over-1-billion/
News Sanofi reports positive phase 3 insulin data HannahBlake 0 Comment Full results from Sanofi’s phase three clinical trials of its investigational new insulin U300 have been announced. The Share X Sanofi reports positive phase 3 insulin data https://pharmaphorum.com/news/sanofi-reports-positive-phase-3-insulin-data/
Cancer/ News Celgene, OncoMed sign $155m cancer deal HannahBlake 0 Comment OncoMed Pharmaceuticals and Celgene Corporation have signed an agreement to jointly develop and commercialize up to six anti-cancer Share X Celgene, OncoMed sign $155m cancer deal https://pharmaphorum.com/news/celgene-oncomed-sign-155m-cancer-deal/
News Positive phase 3 for Novo Nordisk combination diabetes drug HannahBlake 0 Comment Novo Nordisk has announced that a phase 3 clinical trial of its diabetes drug, Ryzodeg, showed improved control Share X Positive phase 3 for Novo Nordisk combination diabetes drug https://pharmaphorum.com/news/positive-phase-3-for-novo-nordisk-combination-diabetes-drug/
News Forest to acquire US rights to Merck’s schizophrenia drug HannahBlake 0 Comment A subsidiary of Forest Laboratories is to acquire exclusive rights for the schizophrenia drug, Saphris, in the United Share X Forest to acquire US rights to Merck’s schizophrenia drug https://pharmaphorum.com/news/forest-to-acquire-us-rights-to-merck-s-schizophrenia-drug/
News FDA extends review of Biogen’s haemophilia drug HannahBlake 0 Comment The US Food and Drug Administration has extended the initial Prescription Drug User Fee Act (PDUFA) date for Share X FDA extends review of Biogen’s haemophilia drug https://pharmaphorum.com/news/fda-extends-review-of-biogen-s-haemophilia-drug/
